2-AG belongs to the endocannabinoid system, a lipid signaling network composed of endogenous cannabinoids, their G protein-coupled receptors, chiefly cannabinoid receptor type 1 (CB1) and type 2 (CB2), and the enzymes that synthesize and degrade these messengers. Unlike classical neurotransmitters, endocannabinoids are synthesized on demand from membrane lipids and travel backward across synapses to modulate neuronal firing. 2-AG is produced primarily by diacylglycerol lipase (DAGL) from membrane diacylglycerol precursors and is rapidly hydrolyzed by monoacylglycerol lipase (MAGL). This tight enzymatic control means that 2-AG signaling is exquisitely sensitive to metabolic state, dietary composition and tissue-specific enzyme expression, a property that becomes pathological when the system is chronically overdriven.

The review’s most striking thread concerns the brain. In the hypothalamus, CB1 receptors are densely expressed on appetite-regulating circuits, including the NPY/AgRP neurons of the arcuate nucleus that drive hunger. Endocannabinoid signaling at these synapses is orexigenic, meaning it promotes food intake, and it interacts with hormonal signals such as ghrelin and orexin. Studies cited in the review show that the orexigenic effect of ghrelin is mediated through central activation of the endocannabinoid system, and that orexin-A can repress satiety-inducing POMC neurons via stimulation of endocannabinoid signaling, contributing to weight gain. In obesity, peripheral endocannabinoid signaling in the gut also inhibits satiation signaling, blunting the normal gut-brain feedback that terminates a meal. The result is a feed-forward loop: more 2-AG, more reward-driven and hyperphagic eating, more adiposity, and again more 2-AG.

Diet itself may fuel this loop. One landmark study highlighted in the review found that dietary linoleic acid, abundant in modern processed foods, elevates endogenous 2-AG and anandamide levels and induces obesity in animal models. Because 2-AG is synthesized from arachidonic acid-containing membrane lipids, the fatty acid composition of the diet can directly shape the tone of endocannabinoid signaling. This provides a mechanistic bridge between the industrial food environment and the neurobiology of overeating, and it suggests that the obesity pandemic is not simply a failure of willpower but a biochemical consequence of altered lipid substrates reaching the enzymes that manufacture endocannabinoids.

Beyond the brain, the review details how 2-AG acts on adipose tissue, liver, skeletal muscle and pancreas through CB1 and, in immune cells, CB2 receptors. In adipocytes, endocannabinoid signaling promotes adipogenesis, the formation and enlargement of fat cells, and stimulates glucose uptake via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. In the liver, activation of hepatic CB1 receptors stimulates fatty acid synthesis and is required for the development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. Conversely, CB1 receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity, while peripheral CB1 inverse agonism reduces obesity by reversing leptin resistance. These findings establish the endocannabinoid system as a genuine peripheral regulator of energy storage, not just a central appetite switch.

At the molecular level, the review maps how 2-AG signaling intersects with canonical metabolic pathways. CB1 activation couples to the insulin/PI3K/AKT axis, with evidence that CB1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 (FOXO1) activity in obese mice. It also modulates AMP-activated protein kinase (AMPK), the cellular energy sensor: CB1 blockade has been shown to ameliorate hepatic fat infiltration and inflammation while increasing the Nrf2-AMPK pathway in diabetic rat models, and the CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity. Interactions with peroxisome proliferator-activated receptors (PPARs) and the inflammatory transcription factor NF-κB further entangle endocannabinoid tone with lipid metabolism and inflammation. The review argues that these convergences allow elevated 2-AG to amplify metabolic dysfunction across multiple pathways simultaneously, which helps explain why obesity is so often accompanied by insulin resistance, fatty liver disease and chronic low-grade inflammation as a coherent syndrome rather than as separate conditions.

Mitochondria emerge as a particularly intriguing nexus. Endocannabinoid signaling influences mitochondrial biogenesis and oxidative metabolism in adipocytes: CB1 blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white fat cells and can induce transdifferentiation of white adipocytes toward a brown fat phenotype, which burns energy rather than storing it. CB1 receptors also mediate depot-specific effects on differentiation, inflammation and oxidative metabolism in different white adipose tissue depots. Because impaired mitochondrial function in muscle and fat is a hallmark of insulin resistance and lipotoxicity, the review suggests that 2-AG-driven suppression of mitochondrial oxidative capacity may be a key mechanism linking endocannabinoid overactivity to the metabolic inflexibility observed in obesity and type 2 diabetes.

Inflammation is the third pillar of the review’s argument. Obese adipose tissue is infiltrated by macrophages, and the polarization of these immune cells toward pro-inflammatory M1 states drives systemic insulin resistance. Here the two cannabinoid receptors diverge sharply. CB1 signaling in macrophages appears to worsen metabolic inflammation: decreasing CB1 signaling in Kupffer cells, the liver’s resident macrophages, improves insulin sensitivity in obese mice, and CB1 blockade attenuates adipose tissue inflammation through microRNA-mediated regulation of macrophage signaling. CB2, by contrast, is largely anti-inflammatory. CB2 agonists such as JWH-133 attenuate chronic inflammation by restraining M1 macrophage polarization via the Nrf2/HO-1 pathway in diet-induced obese mice, and CB2 activation has been implicated in reducing fat storage and promoting adipose browning. The review, which builds on the group’s earlier work on CB2 in hepatic steatosis and fibrosis, frames selective CB2 activation and peripheral CB1 blockade as complementary pharmacological strategies.

The therapeutic history of this field is cautionary but instructive. The CB1 antagonist SR141716 (rimonabant) produced robust weight loss and improved metabolic parameters in diet-induced obese mice and was briefly approved in Europe, but it was withdrawn after psychiatric adverse events, a consequence of blocking CB1 receptors in the brain. The lesson, the authors argue, is that future therapies must target the periphery or the enzymes that control 2-AG levels rather than central receptors wholesale. Inhibitors of DAGL, the synthetic enzyme for 2-AG, and MAGL, its degradative enzyme, offer such an approach, and DAGL inhibition has already shown efficacy in preclinical models of excessive reward-driven intake. Peripherally restricted CB1 antagonists and CB2 agonists, including plant-derived compounds such as beta-caryophyllene, a dietary CB2 ligand, represent additional avenues. Even exercise appears to retune the endocannabinoid system in high-fat diet-induced obesity, suggesting lifestyle interventions may partly work through this axis.

The review is careful to distinguish direct evidence for 2-AG from extrapolation, noting that much of the mechanistic data comes from rodent models and that human studies, such as the finding that plasma 2-AG is a biomarker of age- and menopause-related insulin resistance and dyslipidemia in lean individuals, remain limited. Yet the convergence of evidence across the gut-brain-adipose axis is compelling. If 2-AG truly sits at the crossroads of appetite, adipogenesis, insulin signaling, mitochondrial function and inflammation, then modulating the 2-AG/endocannabinoid axis with tissue-selective tools could yield the next generation of obesity treatments, ones that address the disease’s biology rather than only its energy arithmetic. As obesity reaches pandemic proportions in every household, decoding this fat-derived signal may prove one of the most consequential tasks in metabolic medicine.

Subject of Research: The role of the endocannabinoid 2-arachidonoylglycerol in obesity, inflammation and metabolic dysfunction

Article Title: Beyond energy balance: 2-arachidonoylglycerol at the crossroads of obesity, inflammation, and metabolic dysfunction

Article References: Kumari, S., Nayak, B., & Deshmukh, R. (2026). Beyond energy balance: 2-arachidonoylglycerol at the crossroads of obesity, inflammation, and metabolic dysfunction. Molecular Biology Reports, 53(1), Article 1706. https://doi.org/10.1007/s11033-026-12909-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12909-1

Keywords: 2-arachidonoylglycerol, endocannabinoid system, obesity, CB1 receptor, CB2 receptor, inflammation, insulin resistance, hypothalamus, adipose tissue, mitochondria, MAGL, metabolic dysfunction

PTSD is a chronic psychiatric condition that can develop after traumatic experience, marked by intrusive re-experiencing, hyperarousal and enduring avoidance. Despite decades of clinical work, the underlying neurobiology remains incompletely understood, and existing interventions often deliver limited relief. Growing evidence points to the extended amygdala, and particularly the BNST, as central to the transition from acute, short-lived fear to the prolonged, sustained threat responses that define the disorder. Unlike the amygdala proper, which specializes in phasic fear, the BNST is preferentially recruited by uncertain, sustained and anticipatory threat, making it an especially relevant target for studying trauma that lingers.

The ovBNST is a small, discrete compartment within the anterolateral BNST complex, and it receives a strong and anatomically defined input from the posterior basolateral amygdala (pBLA), a region that integrates socially and emotionally salient contextual information. In the new work, the researchers combined viral tracing with RNAscope single-molecule in situ hybridization to characterize this pathway. They found that roughly 77 percent of pBLA neurons projecting to the ovBNST express the gene encoding the cannabinoid type-1 receptor (CB1R), the presynaptic receptor through which endocannabinoids exert their inhibitory effects. Moreover, about 92 percent of these projecting neurons were glutamatergic, meaning the pathway delivers excitatory signals that endocannabinoids are positioned to dial down.

To model PTSD, the team developed a modified five-day chronic social defeat stress (CSDS) paradigm in which mice are repeatedly exposed to aggressive CD-1 residents. Stressed mice subsequently avoided unfamiliar mice, spent most of their time huddled in corners away from social targets, showed reduced exploration of open and central spaces in anxiety tests, and displayed anhedonia and despair-like behaviors in sucrose preference and forced swim assays. Notably, the shortened five-day protocol induced social avoidance more efficiently than the conventional ten-day version, and it produced comparable behavioral changes in female mice, strengthening the model’s relevance.

In vivo fiber photometry revealed that ovBNST neurons are robustly activated by both acute defeat and chronic stress, and that stressed animals show exaggerated ovBNST responses upon re-encountering an aggressor. Whole-cell electrophysiology in brain slices uncovered the synaptic correlate: miniature excitatory postsynaptic current frequency was elevated after CSDS while amplitude was unchanged, indicating increased presynaptic glutamate release. Critically, blocking CB1Rs with the antagonist AM251 increased excitatory drive in both stressed and control neurons, but the effect was markedly smaller in stressed tissue, showing that the endogenous cannabinoid-mediated restraint on excitatory transmission had been substantially weakened by chronic stress.

At the molecular level, chronic stress reduced Cnr1 mRNA in the pBLA, cutting the proportion of positive neurons from 9.1 to 4.2 percent, and lowered CB1R protein in the ovBNST by about 28 percent. Using a genetically encoded fluorescent sensor called eCB2.0, the researchers directly visualized endocannabinoid release from pBLA terminals in the ovBNST in real time. Acute social defeat triggered a sustained endocannabinoid surge lasting more than fifty seconds, and after chronic stress, subsequent social re-exposure evoked an even larger release. Together, these data suggest the system tries to compensate: postsynaptic neurons pump out more endocannabinoid, but the presynaptic receptors that should receive the signal are disappearing.

The causal tests were striking. Infusing JZL195, which blocks the enzymes that degrade both major endocannabinoids, directly into the ovBNST before behavioral testing normalized social approach, restored anxiety-like measures, and rescued the shortened duration of individual social interactions in stressed mice. A more selective inhibitor, JZL184, which targets MAGL and thereby preserves the abundant endocannabinoid 2-arachidonoylglycerol (2-AG), produced the same benefits. Strikingly, systemic administration of JZL184, which acts throughout the brain, gave minimal improvement, underscoring that the therapeutic effect depends on acting within the right circuit rather than globally amplifying cannabinoid signaling.

The team then went further with projection-specific tools. Using optoCB1R, a light-activated version of the cannabinoid receptor expressed selectively in pBLA neurons, they showed that shining light onto pBLA terminals in the ovBNST during trauma re-exposure pushed stressed mice back to control-level performance, with social interaction ratios exceeding 1.2 and doubled social engagement. Conversely, using a Cre-dependent CRISPR-Cas9 strategy to knock down Dagla, the gene encoding the 2-AG synthesis enzyme DAGLα, only in ovBNST cells innervated by pBLA inputs made mice more vulnerable: under a truncated three-day stress regimen that normally causes no symptoms, DAGLα-depleted mice developed social avoidance and anxiety-like behavior. The knockdown reduced Dagla mRNA to 22 percent of control levels and had no behavioral effect in unstressed animals, confirming the interaction with stress exposure.

The mechanistic picture that emerges is one of a negative feedback loop turned pathological. During acute social threat, postsynaptic ovBNST neurons release 2-AG, which travels backward across the synapse to activate presynaptic CB1Rs on glutamatergic pBLA terminals, dampening further excitation and preventing overgeneralization of threat. With chronic stress, sustained endocannabinoid demand and receptor downregulation dismantle this brake, allowing recurrent amygdala excitation to drive pathological ovBNST hyperactivity, which manifests behaviorally as persistent avoidance and anxiety. This explains why human PET studies of CB1R availability in PTSD have yielded seemingly contradictory results, since receptor changes are region- and symptom-dependent rather than uniform across the brain.

Therapeutically, the work argues for circuit-targeted rather than systemic cannabinoid modulation. Broad CB1R activation carries known risks of cognitive and motor impairment and receptor desensitization, whereas restoring signaling only where it has failed could minimize off-target effects. The authors also caution that important questions remain: the mouse model captures behavioral dimensions rather than the full diagnostic syndrome, the eCB2.0 sensor cannot distinguish 2-AG from anandamide, and PTSD prevalence, BNST organization and endocannabinoid function all differ by sex, while the full circuit-level analysis was performed mainly in males. Still, by identifying a discrete synapse where the brain’s native cannabis-like chemistry gates the persistence of trauma-like states, the study offers a concrete, testable target for the next generation of PTSD treatments.

Subject of Research: Endocannabinoid signaling in the oval bed nucleus of the stria terminalis and PTSD-like behaviors in mice

Article Title: The oval bed nucleus of the stria terminalis endocannabinoid signaling constrains post-traumatic stress disorder-like behaviors

Article References: Zuo, H., Li, J., Li, J., Zhang, X., & Zhang, B. (2026). The oval bed nucleus of the stria terminalis endocannabinoid signaling constrains post-traumatic stress disorder-like behaviors. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.015

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.015

Keywords: PTSD, endocannabinoid, ovBNST, bed nucleus of the stria terminalis, CB1 receptor, 2-AG, social defeat stress, pBLA-ovBNST circuit, anxiety, social avoidance, fiber photometry, optogenetics

A new pair of field studies, published in BMC Medicine, offers the most detailed real-world picture to date. A research team led by Michael Siebers and Johannes Fuss of the University of Duisburg-Essen, together with colleagues at the University Hospital Ulm, the German Sport University Cologne, the University Medical Center Mainz, and other institutions, tracked circulating endocannabinoid concentrations in trained runners during actual competitions, from a standard 42.2-kilometer marathon all the way up to 230-kilometer ultramarathons. Their results reveal a strikingly time-dependent chemical choreography, with one key messenger climbing steadily for hours while a second behaves in a surprisingly selective, distance-dependent manner.

The endocannabinoid system is built around lipid messengers that are synthesized on demand from membrane fats and act on two G-protein-coupled receptors, CB1 and CB2. CB1 receptors are densely expressed in brain regions governing mood, anxiety, and pain perception, which is precisely why the system has been a leading suspect in the runner’s high. The two most studied messengers are anandamide (AEA), an arachidonate-derived ethanolamide whose name derives from the Sanskrit word for bliss, and 2-arachidonoylglycerol (2-AG), which belongs to a different chemical family but activates the same receptors. Both are rapidly degraded by dedicated enzymes, fatty acid amide hydrolase for AEA and monoacylglycerol lipase for 2-AG, meaning their blood levels reflect a dynamic balance of production and clearance rather than a passive accumulation.

In the first study, 19 trained runners completed both a full marathon and a duration-matched walking session on separate occasions, an elegant design that held exercise duration constant while varying the intensity and the mode of locomotion. During the marathon, the researchers drew blood at every 14-kilometer checkpoint and again after a 45-minute recovery break, allowing them to chart the trajectory of five lipid signals: AEA, 2-AG, its structural isomer 1-AG, arachidonic acid, and palmitoylethanolamide, an anti-inflammatory lipid that does not bind CB1. Mood was captured with visual analog scales rating euphoria, anxiety, and pain, the three core psychological features of the runner’s high. All measurements were quantified with a standardized liquid chromatography and multiple reaction monitoring assay, the gold-standard technique for targeted lipidomics.

The headline finding concerns anandamide. AEA concentrations rose progressively throughout the marathon and, remarkably, remained elevated even after 45 minutes of rest, indicating that the signal is not a fleeting byproduct of exertion but a sustained shift in circulating lipid tone. By contrast, the duration-matched walking session produced only modest changes in AEA, suggesting that sustained moderate-to-vigorous intensity, not merely hours of movement, is what drives the messenger upward. The ultramarathon study reinforced this pattern: 36 runners competing over 100, 160, or 230 kilometers all finished with AEA levels above their own baselines, regardless of race distance. Whatever mechanism pushes anandamide into the bloodstream, it appears to engage early and keep working across an extraordinary range of exercise durations.

2-AG told a different and more nuanced story. In the marathon, 2-AG increased significantly only during the later stages of running and remained elevated into early recovery, a delayed profile that contrasts sharply with the steady climb of AEA. In the ultramarathon cohort, 2-AG was not elevated during the races themselves in the same way, but post-race concentrations were increased at all three distances, consistent with what the authors interpret as a delayed, recovery-related response rather than an acute exercise signal. This dissociation matters scientifically: it suggests that the two major endocannabinoids are regulated by partly independent mechanisms during prolonged endurance exercise, with AEA tracking the ongoing stress of running and 2-AG lagging behind, perhaps reflecting lipid remodeling or delayed enzymatic activity that continues after the finish line.

The psychological measurements added a crucial affective dimension. Marathon running was associated with significantly higher euphoria and lower anxiety than duration-matched walking, even though both activities lasted the same amount of time. Pain, however, told a more complicated tale: it increased after the 28-kilometer mark of the marathon, showing that the analgesic component of the runner’s high does not simply overwhelm accumulating musculoskeletal damage during very long efforts. In the ultramarathoners, post-race profiles showed increased pain, reduced anxiety, and no significant change in euphoria. Taken together, these patterns hint that different facets of the runner’s high may ride on different chemical rails, with the anxiolytic effect potentially linked to the sustained AEA rise and the euphoric peak perhaps requiring conditions, such as the intensity profile of a marathon, that ultramarathon pacing does not reproduce.

The field-based design is both the study’s greatest strength and its defining constraint. By sampling real competitors mid-race, the researchers captured physiological conditions that no laboratory protocol can faithfully simulate, including accumulated fatigue, dehydration, heat stress, and the psychological texture of competition. The trade-offs are equally real: field studies cannot control diet, pacing, sleep, or terrain with laboratory precision, and blood-based lipid measurements are an indirect window onto brain chemistry, since circulating endocannabinoids do not map one-to-one onto signaling within the central nervous system. The authors also note that the findings document robust correlations between eCB dynamics and affective states during prolonged running; establishing causation, for example by pharmacologically manipulating the system during exercise, remains a challenge for future work.

Even so, the implications are considerable. The endocannabinoid system is a validated target of both cannabis pharmacology and mainstream drug development, and exercise is increasingly recognized as a natural modulator of this network with potential relevance for mood disorders, chronic pain, and stress resilience. Demonstrating that hours of running produce sustained, intensity-dependent elevations of anandamide in real athletes provides an evolutionary and physiological scaffold for the idea that long-distance locomotion is intrinsically rewarding, a hypothesis sometimes framed as the endurance-exercise model of human origins, in which our ancestors’ capacity for persistence hunting and long-distance travel was reinforced by neurochemical rewards. The persistence of elevated AEA into recovery also raises practical questions about whether the mood benefits of a long run outlast the run itself, a possibility the marathon data directly support at the 45-minute mark.

What emerges from these two studies is a revised and richer picture of the runner’s high: not a single chemical switch flipped at some magical mileage, but a layered, time-dependent process in which anandamide builds steadily with sustained effort, 2-AG responds late and lingers into recovery, and the subjective experience, euphoria, calm, and pain, shifts in ways that only partially overlap with the lipid signals. For the millions of runners who chase that elusive feeling each weekend, the new work offers both validation and humility. The chemistry of bliss is real, measurable in a vial of blood taken at kilometer 28, and it follows rules that science is only now beginning to read, one marathon and one ultramarathon at a time.

Subject of Research: Endocannabinoid signaling dynamics during marathon and ultramarathon running and their relationship to acute mood and pain responses

Article Title: Endocannabinoid dynamics across marathon and ultramarathon running: evidence from two field studies

Article References: Siebers, M., Huvermann, D., Siebers, C., Canales-Romero, D., Florea-Ghile, A., Keite, L., John, L., Munk, M., Bizjak, R., Witzel, J., Schulz, S., Kirsten, J., Bindila, L., Hinney, A., Grau, M., Bizjak, D. A., Engler, H., & Fuss, J. (2026). Endocannabinoid dynamics across marathon and ultramarathon running: evidence from two field studies. BMC Medicine, 24(1), Article 469. https://doi.org/10.1186/s12916-026-05186-z

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05186-z

Keywords: endocannabinoids, anandamide, 2-arachidonoylglycerol, runner's high, marathon, ultramarathon, endurance exercise, CB1 receptor, lipidomics, euphoria, anxiety, pain perception

The syndrome arises from an expansion of CGG repeats in the fragile X messenger ribonucleoprotein 1 gene, or FMR1, on the X chromosome. This expansion silences the gene through hypermethylation, eliminating production of its protein, FMRP. That protein is an RNA-binding molecule with a critical job: it shuttles to both pre- and postsynaptic compartments of neurons, where it fine-tunes local mRNA translation to maintain synaptic plasticity and connectivity. It also influences transcription factors, chromatin-modifying enzymes, and other RNA-binding proteins. When FMRP is absent, the consequences ripple outward, producing the mild cognitive deficits, hyperactivity, and autistic-like behaviors seen in both patients and the widely used Fmr1 knockout mouse model.

Previous work from the same group had already shown that inhibiting CB1, the main receptor of the endocannabinoid system, improves cognitive performance in fragile X mice. Low doses of rimonabant, a selective CB1 antagonist, resolved the aberrant mGluR5-dependent long-term depression and the abnormal hippocampal spine density characteristic of the model. What remained unknown was the molecular machinery underlying those improvements. The new study, led by Lucía de los Reyes-Ramírez and Andrés Ozaita of the Universitat Pompeu Fabra in Barcelona, together with bioinformatician Eduardo Eyras, set out to find that machinery by looking somewhere no one had looked before: inside the synaptoneurosomes, the tiny sealed vesicles that capture both sides of a neuronal connection.

Synaptoneurosomes are essentially pinched-off synaptic terminals, preserving the pre- and postsynaptic machinery in a single preparation. Because FMRP is highly concentrated at synapses, the team reasoned that these structures would offer a far more sensitive window into fragile X pathology than bulk brain tissue. To test this, they split single hippocampi from wild-type mice into two fractions, one processed as bulk homogenate and one enriched for synaptoneurosomes, and sequenced the RNA from both. The fractionation method, not the individual mouse, emerged as the dominant factor shaping the transcriptome. Compared with bulk tissue, synaptoneurosomes were enriched for 749 genes and depleted of 1,019, with the enriched set dominated by Gene Ontology terms related to synapses, transmembrane transport, and mitochondrial activity. More than half of the enriched biological processes were tied to synaptic organization, synaptic plasticity, and mitochondrial bioenergetics, confirming that the preparation genuinely concentrates the synaptic transcriptome.

With that foundation in place, the researchers turned to fragile X mice. Comparing synaptoneurosomes from knockout animals with those of wild-type littermates revealed 29 upregulated and 19 downregulated genes, including changes in genes linked to dendritic arborization, ERK signaling, synaptic transmission, and mTORC1 signaling. The team then treated fragile X mice with rimonabant at 0.1 milligrams per kilogram for seven days, a dose and schedule previously shown to improve cognitive performance and synaptic plasticity. The drug modified the expression of 14 genes in fragile X synaptoneurosomes, and crucially, three of them, Mff, Hnrnpd, and Slain2, moved in the opposite direction to the fragile X signature, effectively reverting toward normal. Quantitative PCR in a larger independent cohort confirmed the reversal for Mff and the fragile X downregulation of Hnrnpd, an RNA-binding protein involved in synapse formation and plasticity. Strikingly, none of these changes appeared when the same animals’ bulk hippocampal tissue was analyzed, underscoring how easily synaptic signals are diluted in whole-tissue preparations.

Because Hnrnpd encodes a direct regulator of mRNA, the team next examined the data at the level of individual transcripts rather than genes, a finer-grained approach that captures the different versions a single gene can produce. This differential transcript expression analysis revealed 254 transcripts altered in fragile X synaptoneurosomes, with enrichment in synapse structure and organization and, notably, in mRNA processing and RNA splicing. Splicing factors such as Celf2 and members of the Hnrnp family were among the downregulated transcripts. When rimonabant was given to fragile X mice, 211 transcripts changed, and the upregulated set was enriched for synapse organization, mRNA splicing, and neuron differentiation, including transcripts from spliceosome-associated genes such as Samd4b, Acin1, and several Hnrnp family members. In wild-type mice, rimonabant produced a completely different and functionally unremarkable pattern, demonstrating that the drug’s effects on the synaptic transcriptome are genotype dependent.

The overlap between the two comparisons was the study’s most striking quantitative result. Of the 254 transcripts altered in fragile X synaptoneurosomes, 34 percent shifted in the opposite direction after rimonabant treatment. More than half of the transcripts downregulated in fragile X animals, 59 out of 109, were restored by the drug, a statistically robust rescue confirmed by hypergeometric testing. Every Gene Ontology term associated with those rescued transcripts related to mRNA processing and splicing, reinforcing the idea that rimonabant ameliorates fragile X synaptic defects by acting on the splicing machinery itself.

That hypothesis was put to a direct test by mapping the alternative splicing landscape, the pattern by which exons are included, skipped, or reconnected to generate different protein isoforms. The absence of FMR1 dysregulated the splicing of 206 genes through 259 alternative splicing events, with alternative first exons and skipped exons the most prevalent categories. Among the affected genes were Cpeb2, FosB, Arf4, Cacng5, and Vdac3, all implicated in synaptic transmission or morphology. Rimonabant modified 178 splicing events in 130 genes in fragile X synaptoneurosomes, and 77 events across 56 genes were common to both the genotype and treatment comparisons, moving in opposite directions. Cross-referencing those 56 genes with a single-cell hippocampal atlas showed that roughly two-thirds are predominantly expressed in neurons, and the affected genes spanned RNA processing, cytoskeleton modulation, ion channels, neuronal development, and mitochondrial function. Most of these events were not significantly altered in rimonabant-treated wild-type mice, indicating a genetic context-specific rescue.

To validate these findings independently, the team designed custom TaqMan probes for three RNA-binding proteins, Ddx6, Celf1, and Cpeb2, and measured both the inclusion and exclusion isoforms of each splicing event in a new, larger set of samples. Ddx6 exon inclusion was downregulated in fragile X synaptoneurosomes and restored by rimonabant, with matching results for exon exclusion. Celf1 transcripts were significantly more abundant after treatment, and Cpeb2 exon inclusion, reduced in fragile X animals, was restored by the drug. The Cpeb2 event was particularly compelling: inclusion or exclusion of a 90-base-pair exon yields two isoforms that differentially regulate RNA translation, and the inclusion isoform is linked to translation activation while the exclusion isoform represses it. Because Cpeb2 controls the translation of neuron-specific mRNAs essential for synaptic plasticity, the researchers propose that its splicing rescue could help normalize the excessive local protein synthesis thought to underlie fragile X synaptic deficits. None of these isoform changes appeared in bulk hippocampal homogenates.

The authors are careful to frame the mechanism as indirect. Given the genes bearing splicing events, FMRP is unlikely to be a direct splicing regulator; instead, it appears to mediate RNA processing by controlling other downstream RNA-binding proteins, many of them brain-specific, that in turn govern synaptic transmission. By restoring the splicing patterns of proteins like Celf1 and Cpeb2, CB1 inhibition may trigger a cascade that normalizes the synaptic microenvironment, potentially including the excitatory-inhibitory balance that is a common feature of autism and fragile X. The study has limitations: only male mice were used, the enriched synaptic fraction may contain other cell types, rimonabant was withdrawn from clinical use and remains an experimental tool, and the splicing changes detected by high-throughput sequencing were subtler when validated by qPCR. Even so, the work establishes that the endocannabinoid system actively modulates the synaptic splicing machinery, and that a previously invisible layer of RNA regulation at the synapse may be a critical step in rescuing fragile X phenotypes. Further studies will determine whether these RNA changes translate into specific protein isoforms capable of restoring fragile X synaptic physiology in humans.

Subject of Research: Restoration of synaptic alternative splicing by CB1 receptor inhibition in a fragile X syndrome mouse model

Article Title: CB1 receptor inhibition restores synaptoneurosomal alternative splicing landscape in fragile X syndrome mice

Article References: Reyes-Ramírez, L. D. L., Ciaran-Alfano, L., Reixachs-Solé, M., Bergadà-Martínez, A., Galera-López, L., Martínez-Torres, S., Navarro-Romero, A., Maldonado, R., Eyras, E., & Ozaita, A. (2026). CB1 receptor inhibition restores synaptoneurosomal alternative splicing landscape in fragile X syndrome mice. iScience, 29(11), Article 117793. https://doi.org/10.1016/j.isci.2026.117793

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117793

Keywords: fragile X syndrome, CB1 receptor, rimonabant, alternative splicing, synaptoneurosomes, FMRP, endocannabinoid system, RNA-binding proteins, hippocampus, autism spectrum disorder, transcriptomics, synaptic plasticity

At the center of the review is the endocannabinoid system, the body’s own lipid signaling network that cannabis hijacks so effectively. The system’s principal receptor, CB1, is one of the most densely expressed G-protein-coupled receptors in the mammalian brain, sitting presynaptically on axon terminals throughout the cortex and striatum. When endogenous cannabinoids such as anandamide and 2-arachidonoylglycerol are released, they travel backward across the synapse and dampen neurotransmitter release, acting as a short-range feedback brake on neural communication. Tetrahydrocannabinol, the main intoxicating component of cannabis, mimics these messengers but with far greater potency and duration, flooding the same circuits and disrupting the finely tuned timing they normally regulate. The review emphasizes that chronic exposure produces dysregulation of CB1 signaling and of the enzymes that synthesize and degrade endocannabinoids, and that this dysregulation maps directly onto the cortico-striatal circuits that govern reward learning, habit formation, and impulse control.

Equally important is the system’s role in stress biology. The endocannabinoid system modulates the hypothalamic-pituitary-adrenal axis and acts within the amygdala and prefrontal cortex to buffer the physiological response to stress. Withdrawal from cannabis, by contrast, is characterized by irritability, anxiety, sleep disturbance, and heightened stress reactivity, a picture consistent with a temporarily depleted endocannabinoid buffer. The review frames craving and relapse as failures of this buffer under load, which explains why stress is such a powerful trigger for relapse in people trying to cut down. This circuit-level account also explains why the disorder shares neurobiological ground with other addictions, while retaining features, such as the uniquely dense CB1 expression in cortical areas, that make it pharmacologically distinct.

Genetics adds a second, complementary layer of evidence. Large-scale genome-wide studies have identified polygenic vulnerability to cannabis use disorder involving loci such as FOXP2, NPTX1, CHRNA2, and PDE4B. Each of these genes points to a different biological process. FOXP2 is a transcription factor best known for its role in speech and motor circuit development, suggesting that neurodevelopmental pathways shape susceptibility. NPTX1 encodes a neuronal pentraxin involved in excitatory synapse maturation, implicating glutamatergic plasticity in the remodeling of reward circuits. CHRNA2, a nicotinic acetylcholine receptor subunit, hints at crosstalk between cholinergic signaling and cannabinoid systems, while PDE4B, a phosphodiesterase that degrades cyclic AMP, ties vulnerability to intracellular signaling and neuroimmune function. The authors stress that no single variant is decisive; rather, risk is distributed across many loci of small effect, which is precisely the kind of architecture that demands large datasets and careful stratification before it can be translated into the clinic.

The therapeutic section of the review is where the framework becomes concrete. Several mechanism-based candidates have now reached early-phase clinical trials, and although none has yet secured regulatory approval, the pattern of results offers proof of concept that targeting the endocannabinoid system can move clinical endpoints. Fatty acid amide hydrolase inhibitors, which block the enzyme that degrades anandamide, aim to amplify the brain’s own cannabinoid signaling in a controlled, spatially restricted way, in contrast to the global receptor activation produced by smoked cannabis. The logic is elegant: rather than flooding every synapse, the drugs strengthen endocannabinoid tone only where and when neurons are already releasing the messengers, potentially easing stress and withdrawal without producing intoxication.

Perhaps the most striking new class is the signaling-specific CB1 modulators, exemplified by the compound AEF0117. Traditional CB1 antagonists failed in the clinic years ago, largely because complete blockade of the receptor produced psychiatric side effects, including anxiety and depression risk. AEF0117 belongs to a generation of molecules designed to be more selective: it blocks the receptor’s signaling toward certain intracellular pathways while leaving others intact, aiming to suppress the reinforcing effects of THC without dismantling the receptor’s role in mood regulation. Early trials suggest this approach can attenuate the subjective reward of cannabis and reduce use, a result that, if confirmed in larger studies, would represent the first mechanism-based pharmacotherapy for the disorder. Alongside these targeted agents, cannabidiol has shown promise in reducing craving and reinforcement, and the review notes that selected repurposed drugs, developed for other indications, have also demonstrated proof-of-concept effects on withdrawal and use.

What elevates the review beyond a catalog of drug candidates is its insistence on heterogeneity. Cannabis use disorder is not one illness but a family of presentations that differ by biological sex, age of onset, psychiatric comorbidity, and patterns of consumption. Sex differences are particularly well documented: women appear to progress from casual use to disorder more rapidly, report different withdrawal profiles, and may respond differently to interventions, a pattern echoed in preclinical work showing sex-biased changes in gene expression networks after adolescent cannabis exposure in animal models. Comorbid anxiety, depression, and psychosis-spectrum symptoms further complicate the picture, since the same endocannabinoid circuits implicated in addiction also modulate mood and cognition. A treatment that works for a young man with heavy daily use and no comorbidities may fail for a woman in her thirties with anxiety-driven relapse, and the review argues that recognizing this is the precondition for precision medicine rather than an obstacle to it.

The precision psychiatry vision the authors sketch is therefore integrative by design. A patient’s endocannabinoid neurobiology, genetic risk profile, clinical presentation, and pattern of use would together inform which mechanism-based treatment is most likely to help. Someone with high stress-driven craving might be matched to an agent that boosts anandamide signaling; someone whose reinforcement circuitry is particularly THC-sensitive might receive a signaling-specific CB1 modulator; someone with strong glutamatergic genetic loading might benefit from interventions aimed at synaptic plasticity. This is not yet possible with current evidence, and the review is careful to frame it as a research agenda rather than a clinical protocol. But the building blocks, validated genetic loci, circuit-level neurobiology, and a growing pipeline of mechanism-specific compounds, now exist in the same place at the same time, which has not been true before.

The unmet clinical need gives this agenda urgency. Rising potency of cannabis products, expanding legalization, and growing global prevalence mean that the number of people with the disorder is climbing even as treatment options remain limited to behavioral therapies, which help many patients but leave a substantial fraction relapsing. The review, published open access with a permanent DOI and supported by funding from Taiwan’s National Science and Technology Council, makes the case that the field should stop treating cannabis use disorder as a monolithic problem awaiting a single blockbuster drug. Instead, it should be approached the way other chronic, heterogeneous conditions have been: by mapping the molecular subtypes, matching treatments to mechanisms, and letting biology, rather than trial-and-error, guide therapy. If that program succeeds, the era in which no approved medication exists for one of the world’s most common substance use disorders may finally be drawing to a close.

Subject of Research: Endocannabinoid neurobiology, genetic vulnerability, and emerging pharmacotherapies for cannabis use disorder

Article Title: Towards precision psychiatry for cannabis use disorder: integrating endocannabinoid neurobiology, genetics, and therapeutic innovation

Article References: Chan, L.-W., Chen, I., Yu, S., & Huang, Y.-C. (2026). Towards precision psychiatry for cannabis use disorder: integrating endocannabinoid neurobiology, genetics, and therapeutic innovation. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04512-6

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04512-6

Keywords: cannabis use disorder, endocannabinoid system, CB1 receptor, precision psychiatry, FAAH inhibitors, AEF0117, cannabidiol, genetics, addiction, withdrawal, Translational Psychiatry, pharmacotherapy

The endocannabinoid system consists of lipid signaling molecules called endocannabinoids, principally anandamide and 2-arachidonoylglycerol, along with their G-protein-coupled receptors, CB1 and CB2, and the enzymes that synthesize and degrade these messengers. CB1 receptors are abundant on nociceptive sensory neurons in the dorsal root ganglia, where their activation dampens the release of pain-transmitting neurotransmitters. CB2 receptors are found predominantly on immune cells, including mast cells and macrophages, and their engagement suppresses the release of proinflammatory cytokines. Beyond these classic receptors, cannabinoids also interact with non-cannabinoid targets such as the ion channel TRPV1, the nuclear receptor PPAR-gamma, serotonin receptors, and orphan G-protein-coupled receptors like GPR18 and GPR55, giving the system an unusually broad pharmacological reach.

What makes this system particularly relevant to endometriosis is that it is not merely a bystander. Human studies have documented elevated systemic levels of endocannabinoids and related mediators across the menstrual cycle in women with endometriosis, and cannabinoid receptor expression has been detected directly in endometriotic lesions. Animal work has shown that the CB1 receptor contributes to the development of ectopic lesions in a mouse model of the disease, while other studies report decreased expression of cannabinoid receptors in the eutopic and ectopic endometrium of patients with adenomyosis, a closely related condition. In other words, the endocannabinoid machinery appears to be rewired in diseased tissue, positioning it as both a marker and a potential driver of pathology.

The review organizes the therapeutic logic of cannabinoids around three mechanistic pillars: inflammation, nociceptive signaling, and lesion proliferation. On the inflammatory front, endometriosis is characterized by a peritoneal environment awash with proinflammatory cytokines, activated macrophages, and degranulating mast cells, all of which sensitize nearby nerve fibers. Cannabinoids attenuate this cascade by inhibiting proinflammatory cytokine signaling and reducing the release of inflammatory mediators from mast cells and peritoneal macrophages. Cannabidiol, the non-psychoactive phytocannabinoid, has been shown in molecular studies to blunt the inflammatory and oxidative processes associated with endometriosis, and CB2-selective agonists reduce cytokine release in blood mononuclear cells. Because neurogenic inflammation, driven by mast cells and nerve fiber interactions, is increasingly recognized as central to endometriosis pain, this immunomodulatory action is a plausible route to symptom control.

The second pillar concerns direct suppression of pain signaling and sensitization. Endometriosis-associated pain involves peripheral, central, and cross-sensitization, in which repeated nociceptive input from pelvic lesions amplifies responses throughout the nervous system, sometimes producing comorbid pain syndromes such as fibromyalgia. Cannabinoids counter this at multiple levels. Activation of peripheral CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception, and genetic studies indicate that cannabinoid analgesia is mediated largely through peripheral type 1 cannabinoid receptors on nociceptors. Cannabidiol acts on TRPV1 signaling pathways in cultured dorsal root ganglion neurons, and CB1 receptor agonists can prevent nerve growth factor-induced sensitization of TRPV1 in sensory neurons, a mechanism directly relevant to the elevated TRPV1 expression observed in the dorsal root ganglia of rats with endometriosis and in peritoneal endometriotic foci of women with chronic pelvic pain.

The third pillar is antiproliferative. Endometriotic lesions behave somewhat like benign tumors, proliferating, invading, and recruiting new blood vessels. Synthetic cannabinoid agonists such as WIN 55212-2 have been shown to target proliferation, angiogenesis, and apoptosis via MAPK/AKT signaling in human endometriotic cell lines and in a murine model of the disease. Cannabinoid agonists exert antiproliferative effects on deep infiltrating endometriosis tissue, and cannabidiol demonstrated anti-inflammatory, antioxidative, and antiangiogenic effects in an experimental rat model. Natural delta-9-tetrahydrocannabinol has even shown disease-modifying effects on endometriosis-associated pain in animal studies, suggesting that cannabinoids might not only mask symptoms but also slow lesion growth, a property that no current medical therapy can claim.

The mechanistic enthusiasm is mirrored by striking epidemiological reality. Surveys from Australia, New Zealand, Canada, Germany, and the United States consistently show that large numbers of women with endometriosis are already using cannabis, often illicitly or without medical supervision, to self-manage their pain, and many report perceived effectiveness. A national survey of Australian women identified cannabis as a common self-management strategy, and international cross-sectional research conducted during the COVID-19 pandemic documented continued and in some cases increased use. National survey data further indicate substantial willingness among women to try cannabis for gynecological conditions. This grassroots adoption has outpaced the clinical evidence, creating a situation in which patients are experimenting on themselves with products of variable composition and dosing, while physicians lack the trial data needed to guide them.

The review’s authors argue that this gap makes properly controlled clinical trials an urgent priority. Several challenges stand in the way. Cannabinoid pharmacology is complicated by the entourage effect, in which combinations of phytocannabinoids and terpenes may produce effects different from isolated compounds, and by the psychoactivity of THC, which limits tolerable doses. However, recent structural and pharmacological advances are opening new doors. The discovery of a cryptic pocket in the CB1 receptor that drives peripheral and functional selectivity suggests it may be possible to design analgesics that activate pain-relieving pathways without central psychoactive effects. Separately, the sodium channel Nav1.8 has been identified as an analgesic target for non-psychotomimetic phytocannabinoids, offering another route to pain relief without intoxication. Such advances could yield peripherally restricted cannabinoid medicines tailored to endometriosis, an approach that would sidestep many of the regulatory and tolerability obstacles that have hampered the field.

There is also an opioid angle that gives the research public-health urgency. Women with endometriosis are frequently prescribed opioids for their pain, and cohort studies in US administrative claims data have documented chronic opioid use and its complication risks in this population. Cannabinoids interact with the opioid system, and a growing body of preclinical and clinical evidence supports an opioid-sparing effect of cannabinoids for analgesia. Because cannabinoid receptor expression has been detected in endometriotic lesions of women with the disease, some researchers have proposed cannabinoid-based approaches as an alternative to opioid-based pain medication. If clinical trials confirm meaningful analgesia, cannabinoids could help reduce opioid exposure in a patient population disproportionately affected by long-term opioid therapy and its attendant risks of dependence and hyperalgesia.

Cautious optimism is the appropriate stance. The evidence base remains dominated by in vitro studies and animal models, and human interventional data are still sparse, while the endocannabinoid system also plays fundamental roles in endometrial and placental biology, raising questions about reproductive safety that trials must address. Yet the convergence of epidemiological demand, mechanistic plausibility across inflammation, nociception, and proliferation, and emerging medicinal chemistry that promises non-psychoactive, peripherally targeted drugs makes the endocannabinoid system one of the most compelling therapeutic frontiers in endometriosis research. As the Wayne State team concludes, the system’s regulation of nociception, inflammation, and lesion growth warrants rigorous clinical evaluation, and for the millions of women whose pain has outlasted every existing therapy, that evaluation cannot come soon enough.

Subject of Research: The role of the endocannabinoid system in the mechanisms and treatment of endometriosis-associated pain

Article Title: The Endocannabinoid System in Endometriosis-Associated Pain: Mechanisms, Molecular Targets, and Therapeutic Implications

Article References: Stone, A. M., Veltre, V. L., Camp, O. G., Biernat, M. M., & Abu-Soud, H. M. (2026). The Endocannabinoid System in Endometriosis-Associated Pain: Mechanisms, Molecular Targets, and Therapeutic Implications. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02201-9

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02201-9

Keywords: endometriosis, endocannabinoid system, cannabinoids, cannabidiol, chronic pelvic pain, CB1 receptor, CB2 receptor, inflammation, nociception, TRPV1, lesion proliferation, clinical trials

The scale of the problem the researchers confront is enormous. According to the United Nations Office on Drugs and Crime, new psychoactive substances are compounds that threaten public health yet fall outside the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. By the end of 2024, the European Union Drugs Agency was monitoring 1,000 such substances in Europe, 47 of them first reported that year. Between 2012 and 2025, the UNODC Early Warning Advisory logged 1,391 new psychoactive substances across 152 countries and territories, while the NPS Discovery program of the Center for Forensic Science Research and Education identified 174 compounds for the first time in the United States between 2018 and 2024, including 20 in 2024 alone. Each new structure demands a rapid toxicological evaluation, and the zebrafish, with its transparent embryos, rapid development, and vertebrate reward circuitry, has become one of the most practical platforms for that task.

The two compounds chosen for this study illustrate the cat-and-mouse dynamics of the synthetic drug market. ADB-INACA is a so-called tail-less precursor, an indazole carboxamide lacking the N-alkyl tail found in potent controlled SCRAs such as ADB-BUTINACA. First flagged by NPS Discovery in 2023, it has since appeared in nine drug-material cases and seven toxicological specimens. CHO-4′Me-5′Br-FUBOXPYRA, by contrast, was engineered with a novel 5-bromo-4-methylpyridin-2(1H)-one core specifically to evade China’s 2021 generic ban on synthetic cannabinoids. First identified in Europe in 2022, it has since surfaced in Germany, Italy, Slovenia, Sweden, Lithuania, Romania, Spain, and, as of 2023, in United States drug material, with a first toxicological detection reported in 2024. Prior receptor studies suggested both compounds carry only limited CB1 activity, making them ideal candidates to test whether structural loopholes translate into genuine physiological risk.

To answer that question, the team, led by Leonardo Costalonga Rodrigues and colleagues at the Universidade Estadual de Campinas in Brazil and the University of Utah, deployed a battery of complementary assays. Acute embryonic toxicity was measured with the fish embryo acute toxicity test standardized by the Organization for Economic Co-operation and Development as guideline 236, in which newly fertilized eggs are exposed to a compound for 96 hours and scored for lethal endpoints: coagulation of the egg, lack of somite formation, failure of the tail bud to detach from the yolk sac, and absence of heartbeat. Concentrations ranged from 0.001 to 10 micromolar, with 16 embryos per concentration, and sublethal observations such as pericardial edema, loss of posture, and heart rate changes were recorded daily under a stereoscopic microscope. At three days post-fertilization, heartbeats of five larvae per group were filmed for 20 seconds and extrapolated to beats per minute, and at four days each larva was touched on the tail with a micropipette tip to test its escape response.

The results from embryonic exposure were strikingly mild. Both SCRAs produced low mortality across the entire tested range, with embryo coagulation the only lethal endpoint observed, and even that appeared in fewer than 19 percent of embryos at any time point. CHO-4′Me-5′Br-FUBOXPYRA, however, did produce sublethal cardiac and postural effects that crossed the study’s 30 percent reporting threshold: pericardial edema at 10 micromolar, loss of posture in 69 percent of larvae at the highest concentration at three days post-fertilization, and a statistically significant reduction in heart rate at 10 micromolar, with a p-value below 0.01. Escape responses were blunted at all concentrations above 0.1 micromolar for this compound. ADB-INACA produced mainly impaired escape responses at select concentrations without significant lethality or cardiac effects. A companion maximum tolerated concentration test in larvae, exposing animals from five to eight days post-fertilization, largely confirmed this picture, with absent escape responses and occasional loss of posture at the highest doses but little else.

The behavioral experiments are where the study breaks genuinely new ground. Social behavior was assessed at 21 days post-fertilization using the Fishbook assay, a scalable, fully automated system first described in 2022. Juvenile zebrafish swim in a three-dimensional-printed rectangular arena divided by transparent windows into a central test compartment, an end compartment holding a live fish as a social stimulus, and an empty end compartment. Forty-four arenas are imaged simultaneously through a telecentric lens system, and software streams frame-by-frame positional coordinates that are converted into a social score between negative one and one, where higher values indicate that a fish spent more time near the social stimulus. Neither compound altered the social score: fish exposed to 10 micromolar ADB-INACA averaged 0.484 versus 0.424 in controls, and fish exposed to 10 micromolar CHO-4′Me-5′Br-FUBOXPYRA averaged 0.658 versus 0.623 in controls. To the researchers’ knowledge, this is the first in vivo evaluation of any SCRA’s impact on social interaction.

The final and arguably most ambitious assay tested whether the new compounds could drive drug-seeking behavior. Building on a paradigm developed by Bossé and Peterson, the team constructed a custom arena with two submersible platforms, an “active” one wired to a Raspberry Pi minicomputer and infrared cameras that trigger a peristaltic pump releasing a drug solution, and an “inactive” one that dispenses nothing. A recirculation system prevented drug diffusion to the inactive corner. Adult zebrafish first learned over five days of food conditioning that crossing the active platform yields a reward, then received five days of drug treatment. Hydrocodone served as the positive control, and it performed as expected: fish consistently sought the opioid, triggering the active platform far more often than the inactive one. Fish exposed to 0.625 micrograms of CHO-4′Me-5′Br-FUBOXPYRA per trigger, however, showed a progressive decline in active-platform crossings indistinguishable from the water-treated controls, indicating the compound lacked reinforcing effects under these conditions. ADB-INACA was not carried into self-administration testing because the earlier toxicity assays had revealed no significant effects.

The authors connect their findings to the wider pharmacological literature on these structural families. Earlier work on tail-less indazole precursors found minimal CB1 receptor activity for ADB-INACA, with concentration-response curves that failed to reach a clear plateau and potency estimates that could not be determined, while brominated analogs showed only partial receptor activation even at 100 micromolar. For CHO-4′Me-5′Br-FUBOXPYRA, a 2025 investigation of its metabolism identified four hydroxylated metabolites and a limited activation potential at both CB1 and CB2. The new zebrafish data align neatly with that weak receptor profile: limited cannabinoid-like behavioral effects, normal social behavior, no drug-seeking, and only modest cardiotoxicity for the brominated pyridone compound in the form of pericardial edema and reduced heart rate at the highest concentration tested. The study does have limitations the authors themselves acknowledge: only two compounds were evaluated, exposures were acute rather than chronic, and no molecular or neurochemical endpoints were measured to confirm what the receptors were doing during the behavioral tests.

Even so, the methodological takeaway may prove more consequential than the individual toxicological verdicts. By combining OECD-standard embryo testing, larval maximum tolerated concentration assays, the automated Fishbook social paradigm, and an operant self-administration assay within a single vertebrate model, the study demonstrates an end-to-end pipeline capable of profiling a novel psychoactive substance from developmental toxicity to abuse liability in a matter of weeks. The authors describe these assays as feasible, reproducible, and translationally relevant, and argue that they can be extended to a much larger number of emerging compounds, offering a rapid toxicological surveillance bridge between preclinical toxicology and public health needs. As forensic chemists continue to identify new SCRAs faster than regulators can schedule them, the humble zebrafish may become one of the fastest ways to learn whether the next designer cannabinoid is a genuine threat or, as appears to be the case for ADB-INACA and CHO-4′Me-5′Br-FUBOXPYRA at the concentrations tested, a structural dodge with surprisingly little punch.

Subject of Research: Toxicity and behavioral effects of the synthetic cannabinoid receptor agonists ADB-INACA and CHO-4′Me-5′Br-FUBOXPYRA in zebrafish models

Article Title: Evaluation of synthetic cannabinoid receptor agonists toxicity in zebrafish (Danio rerio) through self-administration and Fishbook assays

Article References: Rodrigues, L. C., Muhsen, M., Aliabadi, S. R., Zhang, T., Maurer-Morelli, C. V., Peterson, R. T., & Costa, J. L. (2026). Evaluation of synthetic cannabinoid receptor agonists toxicity in zebrafish (Danio rerio) through self-administration and Fishbook assays. Discover Toxicology, 3(1), Article 4. https://doi.org/10.1007/s44339-026-00049-x

Image Credits: AI Generated

DOI: 10.1007/s44339-026-00049-x

Keywords: synthetic cannabinoids, new psychoactive substances, zebrafish, toxicology, ADB-INACA, CHO-4′Me-5′Br-FUBOXPYRA, Fishbook assay, self-administration, drug-seeking behavior, CB1 receptor, embryotoxicity, social behavior

The prespecified primary endpoint was the change in the android-to-gynoid fat ratio, a measure derived from dual-energy X-ray absorptiometry, or DXA, that compares fat stored in the upper body and abdomen with fat stored around the hips and thighs. Because visceral and abdominal fat behave as active endocrine tissue and drive insulin resistance, systemic inflammation, and cardiovascular risk, this ratio is considered a more meaningful index of metabolic danger than body mass alone. After ninety days, participants taking 10 mg of Pep19 showed a reduction in the ratio compared with placebo. The observed difference was 3.19 percentage points in favor of the treated group, and a prespecified mixed-effects model estimated an adjusted treatment effect of −3.58 percentage points, with a 95 percent confidence interval of −6.96 to −0.19 and a p-value of 0.037. Supporting analyses on a logarithmic scale showed a 3.4 percent relative reduction, although the analysis on the absolute scale, with a difference of −0.037 ratio units, narrowly missed conventional significance at p = 0.058. The 5 mg dose did not produce a significant change in the primary endpoint.

What makes these results striking is that overall body composition barely moved. Body weight, body mass index, total fat mass, and percentage of body fat remained statistically unchanged in all three groups, and lean mass was preserved or slightly increased. Yet participants on the higher dose showed significant reductions in total skinfold thickness and abdominal skinfold thickness, while those on the lower dose showed a significant reduction in abdominal circumference. This pattern suggests that Pep19 is not primarily a weight-loss drug but an agent that remodels where fat is stored, steering lipid away from the abdominal and presumably visceral compartments that contribute disproportionately to metabolic disease. The researchers argue that such selective redistribution may explain why metabolic benefits appeared even as the scale stood still.

The metabolic data reinforce that interpretation. Participants receiving 10 mg of Pep19 showed a significant reduction in glycated hemoglobin, or HbA1c, compared with placebo after ninety days, despite stable fasting glucose concentrations. Because HbA1c integrates glucose exposure over roughly three months, this finding points to improved postprandial or integrated glycemic control rather than an acute fasting effect. Meanwhile, the homeostatic model assessment of insulin resistance, known as HOMA-IR, fell significantly in both treatment groups by day ninety, and in the 10 mg group the decline was already evident at day sixty. Insulin concentrations trended downward in both treated groups. The authors note that, unlike conventional antidiabetic drugs that work through insulin secretion, renal glucose excretion, or appetite suppression, Pep19 produced these changes without altering body weight, caloric intake, or lean mass.

Pep19 is a short intracellular peptide with the sequence DIIADDEPLT, and its pharmacology is unconventional. Previous work characterized it as an inverse agonist of the cannabinoid receptor type 1, or CB1R, using conformationally sensitive antibodies. In adipose cells and in rodent models of diet-induced obesity, Pep19 activated ERK1/2 and AKT signaling, upregulated the thermogenic protein uncoupling protein 1, reduced mesenteric visceral fat, lowered triglycerides, cholesterol, and blood pressure, attenuated liver inflammation and hepatic fat accumulation, and stimulated so-called browning of white adipose tissue. Crucially, the peptide showed no central nervous system activity in preclinical tests, failing to produce the cannabinoid tetrad, brain c-fos induction, or depressive and anxious behaviors. This matters because first-generation centrally acting CB1R blockers, such as rimonabant, were withdrawn over neuropsychiatric side effects, and a newer peripheral candidate, monlunabant, recently showed neuropsychiatric signals in a phase 2a trial.

The authors place their findings within a revised view of hepatic CB1R biology. Recent evidence indicates that the receptor behaves differently depending on metabolic state: in lean conditions it promotes Gi/o-mediated lipolysis, whereas in obesity it shifts toward Gs-mediated lipogenesis driven partly by GPR3 and oleic acid priming. One hypothesis is that Pep19 acts as a context-dependent functional modulator that favors a lean-like signaling state, enhancing fatty acid oxidation while suppressing lipogenesis. The trial itself did not measure target engagement or downstream signaling, so the authors are careful to state that mechanistic interpretations remain speculative and must be tested directly in future studies. Still, the framework offers a plausible account of how peripheral CB1R modulation could redirect fat storage and improve insulin sensitivity without weight loss.

One of the most intriguing results emerged from an unsupervised k-means cluster analysis of individual response profiles. Two distinct phenotypes appeared. A large cluster of forty-five participants showed minimal change across all measured features. But a second cluster of eleven participants displayed a coordinated high-response pattern: pronounced reductions in total fat mass, sum of skinfolds, and abdominal skinfold, together with decreases in HOMA-IR and the inflammatory marker tumor necrosis factor-alpha. Remarkably, this cluster consisted exclusively of Pep19-treated participants, six from the 5 mg group and five from the 10 mg group, with no placebo-treated individuals showing the same profile. The authors interpret this as evidence of a responder phenotype, suggesting that future therapeutic use might be optimized through biomarker-guided patient selection, a precision-medicine approach that could be highly relevant in obesity therapeutics where interindividual variability often obscures aggregate treatment effects.

Safety outcomes were reassuring across the board. Renal, hepatic, hematological, and endocrine laboratory parameters remained within normal ranges throughout the intervention, with no treatment-related toxicological signals or clinically relevant abnormalities. Systolic blood pressure trended downward in the high-dose group but did not reach statistical significance, and lipid parameters and inflammatory markers such as C-reactive protein and interleukin-6 did not change significantly, a result the authors attribute to the short ninety-day duration, the predominantly normal baseline lipid status of the cohort, and the fact that systemic inflammation tracks more closely with total adiposity, which did not change. Pep19 already holds generally recognized as safe status in the United States based on FDA scientific procedures, and a previous sixty-day trial in an American cohort found that 5 mg daily reduced visceral fat by roughly seventeen percent on average while lowering body weight only two percent.

The authors acknowledge important limitations. The sample was modest, drawn from a single geographic setting, and the ninety-day follow-up cannot establish durability of effect. Diet and physical activity were self-monitored rather than objectively tracked, and baseline insulin resistance was numerically higher in the 10 mg group, which may have amplified the apparent HOMA-IR improvement. No adipokine profiling or target-engagement biomarkers were assessed. Even so, the consistent pattern across the primary endpoint, anthropometry, and glycemic measures supports further clinical investigation. Because Pep19 acts in a range where conventional drugs are generally not indicated, in otherwise healthy adults with normal or borderline HbA1c and HOMA-IR, it could fill a genuine gap: a safe early intervention that improves metabolic efficiency before irreversible tissue damage occurs, without the lean-mass loss associated with many current weight-loss therapies.

Subject of Research: A randomized controlled trial of the oral peptide Pep19 for improving adipose tissue distribution and metabolic health in adults with obesity

Article Title: Effects of Pep19 on adipose tissue distribution and metabolic parameters in adults with obesity: A randomized, double-blind, placebo-controlled trial

Article References: Vantini, D., Roberto de Sá, J., Sarni, R. O., Hix, S., Filho, F. L., Ruiz, R., Remer, R. A., Krongrad, A., Martucci, L. F., Ferro, E. S., Heimann, A. S., & Fonseca, F. L. (2026). Effects of Pep19 on adipose tissue distribution and metabolic parameters in adults with obesity: A randomized, double-blind, placebo-controlled trial. iScience, 29(10), Article 117471. https://doi.org/10.1016/j.isci.2026.117471

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117471

Keywords: Pep19, obesity, visceral fat, adipose tissue, CB1 receptor, insulin resistance, HbA1c, HOMA-IR, DXA, clinical trial, intracellular peptide, metabolic health